Disease · HP_0000010
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. | 11 of 328 | 29 of 336 | 664 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics. | 30 of 328 | 41 of 336 | 664 | NCT01595529 | Trial comparisons |
| Standard Course Treatment vs Short Course Treatment: Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. | 2 of 328 | 14 of 336 | 664 | NCT01595529 | Trial comparisons |
| Standard Course Treatment vs Short Course Treatment: deaths from any cause | 0 of 328 | 0 of 336 | 664 | NCT01595529 | Trial comparisons |
| Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics. | 6 of 328 | 41 of 336 | 664 | NCT01595529 | Trial comparisons |
| Standard Course Treatment vs Short Course Treatment: serious adverse events | 2 of 328 | 4 of 336 | 664 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics. | 12 of 326 | 13 of 322 | 648 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. Per-protocol Population. | 2 of 308 | 9 of 314 | 622 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population. | 6 of 308 | 35 of 314 | 622 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population | 29 of 308 | 33 of 314 | 622 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population. | 11 of 308 | 29 of 314 | 622 | NCT01595529 | Trial comparisons |
Standard Course Treatment vs Short Course Treatment: Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population. | 10 of 306 | 13 of 305 | 611 | NCT01595529 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000010/comparisons